Clinical trial GRAVITAS-309
A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Cancers | |
---|---|
Organ | NA |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2/3 |
Academic trial | Non |
Sponsor | Incyte Corporate |
EudraCT Identifier | 2018-001606-29 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03584516 |
Inclusion criteria | 1. moderate or severe cGVHD per NIH Consensus Criteria2. KPS score > 60%.3. Evidence of myeloid and platelet engraftment, that is, ANC > 1.0 × 10e9/L and plateletcount > 50 × 10e9/L.4. Has not received more than 3 days/72 hours of systemic corticoster |
Last update |